Stocks Health care RLAY
NASDAQ · Health careRelay Therapeutics, Inc. (RLAY)
It posted a net loss of $293.6M. In fiscal 2025 capital spending exceeded operating cash flow by $235.9M. At September 30, 2026 it held $124.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Relay Therapeutics, Inc.
- Net worth
- Relay Therapeutics, Inc. has a market value (market cap) of $4.3B at the latest share price, and shareholders' equity of $819M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $15.4M (+53.4% year on year), with a net loss of $276.5M.
- Cash flow
- In fiscal 2025 operations used $235.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Relay Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Relay Therapeutics, Inc. does
Relay Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker RLAY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $15.4M | -$276.5M | -$1.61 | -$235.9M |
| 2024 | $10M | -$337.7M | -$2.36 | -$251.1M |
| 2023 | $25.5M | -$342M | -$2.79 | -$304.4M |
| 2022 | $1.4M | -$290.5M | -$2.59 | -$238.6M |
| 2021 | $3M | -$363.9M | -$3.82 | -$77.9M |
| 2020 | $82.7M | -$52.4M | -$5.40 | -$104.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RLAY ranks in Health care
Latest SEC filings
What Relay Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- November 4, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 48% to $350K versus the same quarter last year; diluted EPS -$0.41 versus -$0.41.
- August 6, 2026
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- June 9, 2026
- May 21, 2026
Insider trades
What the people running Relay Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $120.5M worth of shares in the last 90 days and bought none on the open market. 3% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 28, 2026 | Catinazzo ThomasChief Financial Officer | Sold | 1,469 | $27.4K |
| October 28, 2026 | Bergstrom Donald APresident, R&D | Sold | 2,252 | $41.9K |
| October 28, 2026 | Rahmer PeterSee remarks | Sold | 753 | $14K |
| October 7, 2026 | Patel SanjivPresident and CEO, Director | Soldpre-planned (10b5-1) | 48,199 | $872.4K |
| October 6, 2026 | Catinazzo ThomasChief Financial Officer | Soldpre-planned (10b5-1) | 17,511 | $325.4K |
| October 6, 2026 | Catinazzo ThomasChief Financial Officer | Soldpre-planned (10b5-1) | 206 | $4K |
| September 8, 2026 | Patel SanjivPresident and CEO, Director | Soldpre-planned (10b5-1) | 48,199 | $912.9K |
| September 8, 2026 | Catinazzo ThomasChief Financial Officer | Soldpre-planned (10b5-1) | 17,717 | $335.6K |
Who owns RLAY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 10% | August 7, 2026 |
| Casdin Capital, LLC13G, passive with 3 related filers | 7.5% | February 17, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 6.4% | August 10, 2026 |
| Commodore Capital LP13G, passive with 3 related filers | 5.5% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 262 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| SB Investment Advisers (UK) Ltd | 27,904,963 | 0 |
| Fmr LLC | 20,110,113 | +16,414,682 |
| Casdin Capital, LLC | 16,035,240 | +1,616,666 |
| BlackRock, Inc. | 15,288,260 | +2,312,903 |
| Perceptive Advisors LLC | 14,544,658 | +4,793,517 |
| Commodore Capital LP | 12,000,000 | -5,000,000 |
| State Street Corp | 10,125,381 | +3,891,836 |
| Vanguard Capital Management LLC | 8,984,284 | +1,576,958 |
| Nextech Invest Ltd. | 6,776,506 | +1,250,000 |
| Bellevue Group AG | 6,185,970 | -1,609,272 |
| Geode Capital Management, LLC | 4,753,293 | +1,194,807 |
| TCG Crossover Management, LLC | 4,273,356 | 0 |
| Morgan Stanley | 3,852,479 | +2,419,068 |
| Siren, L.L.C. | 3,650,000 | new |
| Goldman Sachs Group Inc | 3,408,701 | +866,840 |
| Westfield Capital Management Co LP | 3,343,496 | new |
| Kynam Capital Management, LP | 3,300,000 | +1,875,741 |
| Dimensional Fund Advisors LP | 3,139,702 | +199,166 |
| Spruce Street Capital LP | 2,984,125 | 0 |
| Vanguard Portfolio Management LLC | 2,892,785 | +1,029,220 |
Insiders
5 insiders reported holding 23,099,711 shares in total, about $457.7M at the last price.
| Holder | Shares |
|---|---|
| SVF Pauling (Cayman) Ltd10% owner | 21,904,96321,904,963 held indirectly |
| Patel SanjivPresident and CEO, Director | 471,301 |
| Bergstrom Donald APresident, R&D | 396,878 |
| Rahmer PeterSee remarks | 222,904 |
| Catinazzo ThomasChief Financial Officer | 103,665 |
Questions about RLAY
What does Relay Therapeutics, Inc. do?
Relay Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as RLAY. Its shares trade on NASDAQ under the ticker RLAY.
What is Relay Therapeutics, Inc.'s net worth?
Relay Therapeutics, Inc. has a market value (market cap) of $4.3B at the latest share price, and shareholders' equity of $819M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Relay Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $293.6M.
When did Relay Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Relay Therapeutics, Inc.'s next earnings report?
Relay Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RLAY with
Follow RLAY
Get an email when Relay Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Relay Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.